Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 331 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Biweekly Cabazitaxel in Patients 65 Years or Older with mCRPC for... November 7, 2023 Analyzing Tumor RNA May Help Match Patients with Most Effective Cancer... March 19, 2020 Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story February 9, 2023 Load more HOT NEWS Elucidating a Risk of Developing Second Primary Malignancy During and After... Activity and Manageable Toxicity of Pembrolizumab in Some Rare and Ultrarare... ¿Las píldoras anticonceptivas afectan mi riesgo de cáncer? Analysis of the Gut Microbiome Provides Clues to Survival Following Nivolumab...
